aPTT

:   activated partial thromboplastin times

ARDS

:   acute respiratory distress syndrome

CPAP

:   continuous positive airway pressure

CT

:   computed tomography

CTHs

:   head CTs

ECMO

:   extracorporeal membrane oxygenation

FDA

:   Food and Drug Administration

ICH

:   intracranial hemorrhage

IPH

:   intraparenchymal hemorrhage

MICU

:   medical intensive care unit

PCR

:   polymerase chain reaction

SARS-CoV-2

:   severe acute respiratory syndrome coronavirus 2

SLE

:   systemic lupus erythematosus

OSA

:   obstructuve sleep apnea

VV

:   veno-venous
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The respiratory illness, COVID-19, caused by the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a sudden onset and rapidly evolving pandemic. The natural progression for those developing the severe and life-threatening form of the disease has been described as clinically similar to acute respiratory distress syndrome (ARDS), often requiring intubation, lung-protective ventilation strategies, proning and extracorporal membrane oxygenation (ECMO).^[@bib1]^ Over the last 3 decades, ECMO has gained increasing traction in the treatment of patients with severe ARDS who develop refractory hypoxia,^[@bib2]^ and has thus been proposed in the treatment of patients with the most severe forms of coronavirus disease 2019 (COVID-19).^[@bib3],[@bib4]^ The most common complications of ECMO are bleeding and thrombosis. Not only do patients on ECMO require therapeutic anticoagulation to maintain therapy, which predisposes patients to additional bleeding complications,^[@bib5]^ but the bypass itself both consumes and damages platelets and dilutes clotting factors.^[@bib6]^ Intracranial hemorrhage (ICH), in the setting of ECMO, is a recognized entity, with rates up to 21%.^[@bib7]^ The most consistent factors that have been demonstrated to increase the risk of ECMO-related ICH have been prehospitalization anticoagulation therapy and thrombocytopenia.^[@bib7],[@bib8]^ Here, we describe 2 patients who required ECMO for refractory hypoxia secondary to COVID-19 and developed neurologically devastating intraparenchymal hemorrhage (IPH) despite lacking the classical risk factors.

CLINICAL PRESENTATION {#sec3}
=====================

Per institutional guidelines, consent was not required and thus was not obtained or sought.

Case 1 {#sec3-1}
------

A 58-yr-old female with a past medical history of diabetes and systemic lupus erythematosus (SLE), who presented with 6 d of cough, fever, and shortness of breath, determined to have COVID-19 with positive SARS-CoV-2 polymerase chain reaction (PCR). The patient\'s respiratory illness had improved with prolonged ECMO, as evidenced by progressively increased areas of aeration on chest X-ray (CXR, Figure [1](#fig1){ref-type="fig"}A and [1B](#fig1){ref-type="fig"}). The patient had been intubated and placed on ECMO prior to transfer (hospital day 1) and was placed prone overnight for 16 h/d beginning on hospital day 16. On hospital day 19, she was noted to have a nonreactive right pupil after being returned supine in the morning. Head CT demonstrated a large volume (8.4 × 4.6 × 4.7 cm) left frontal IPH with a 1.3 cm left to right midline shift, as well as sulcal effacement, and uncal and subfalcine herniation (Figure [2](#fig2){ref-type="fig"}A and [2B](#fig2){ref-type="fig"}). She had been heparinized since the initiation of VV-ECMO with an aPTT of 60 at the time of hemorrhage. Patient was comfortably extubated on hospital day 20 and expired.

![Fifty-eight-year-old (F) patient with past medical history of diabetes and SLE, presented with COVID-19 on ECMO. CXR on day 1 **A** and day 19 **B** after transfer to the heart and vascular intensive care unit (HVICU).](nyaa198fig1){#fig1}

![CTH on HVICU day 19, demonstrating a large-volume dominant hemisphere, frontal IPH, left to right midline shift, and near-complete effacement of the lateral ventricles **A** as well as obliteration of the basal cisterns **B**.](nyaa198fig2){#fig2}

Case 2 {#sec3-2}
------

A 46-yr-old male with a past medical history of hypertension and obstructuve sleep apnea (OSA), on nasal continuous positive airway pressure (CPAP) at home. The patient presented with 7 d of cough, fever, and shortness of breath and was ultimately determined to have COVID-19 with positive SARS-CoV-2 PCR and characteristic infiltrates on lung imaging (Figure [3](#fig3){ref-type="fig"}). He was transferred to the medical intensive care unit (MICU) for progressive respiratory distress and was intubated and transitioned to ECMO on day 6 of admission. On hospital day 13, he was noted to have a fixed and dilated left pupil. Head CT demonstrated a large (6.7 × 6.0 × 5.9 cm) left frontal IPH with a 1.4 cm left to right midline shift, as well as uncal and subfalcine herniation (Figure [4](#fig4){ref-type="fig"}). He had been heparinized since the initiation of VV-ECMO with an aPTT of 71 at the time of hemorrhage. Patient was comfortably extubated and expired.

![Forty-six-year-old (M) patient with a past medical history of HTN and OSA, presenting with COVID-19 on ECMO. CXR on day 0 **A** and on day 5 **B** after transfer to the MICU. **C**, CT chest on MICU day 7.](nyaa198fig3){#fig3}

![**A**, CTH on MICU day 7 with a large-volume frontoparietal IPH displacing the motor strip. **B**, CTH slice with the largest volume of IPH, demonstrating a fluid-fluid level. Also apparent are significant left-to-right midline shift **C** and uncal herniation **D**.](nyaa198fig4){#fig4}

DISCUSSION {#sec4}
==========

ICH is a well-described complication of ECMO, regardless of initial etiology.^[@bib8]^ While it is generally accepted that the risk of bleeding complications on ECMO rises with marked derangements in the clotting cascade,^[@bib9]^ no such alterations could be identified in the COVID-19 patients described here ([Table](#tbl1){ref-type="table"}). Patients on ECMO secondary to viral respiratory illnesses have previously been shown to have a high rate of devastating ICH in the setting of the 2009 H1N1 influenza.^[@bib10],[@bib11]^ While the precise mechanisms underlying this phenomenon remain unclear, this and other series have suggested that microvascular thrombosis may underlie ischemia and subsequent hemorrhage in these patients, a finding that is particularly relevant in the case of COVID-19, for which microvascular thrombosis has been observed as a precipitator of respiratory pathology.^[@bib12]^ In addition, COVID-19 has been hypothesized to cause a cytokine storm, which may result in platelet dysfunction, despite normal platelet counts, as observed here.

###### 

Laboratory Values of COVID-19 Patients on ECMO

  Laboratory value        Reference range   46-yr-old (M) patient (admit)   46-yr-old (M) patient (IPH)   58-yr-old (F) patient (admit)   58-yr-old (F) patient (IPH)
  ----------------------- ----------------- ------------------------------- ----------------------------- ------------------------------- -----------------------------
  White blood cells       4.0-11.0          32.6                            41.3                          5.5                             15.6
  Hemoglobin              13.5-17.5         13.2                            9.0                           13.5                            7.4
  Hematocrit              40-52             39                              26                            43.7                            22
  Platelets               150-400           351                             197                           188                             139
  aPTT                    25.1-36.5         26.3                            70.9                          34.2                            60.3
  PT                      9.4-12.5          15.7                            14.4                          18.1                            17.8^b^
  INR                     0.8-1.1           1.4                             1.3                           1.6                             1.6^b^
  [d]{.smallcaps}-dimer   0.00-0.50         Unavailable                     1.04^b^                       Unavailable                     19.72^c^
  Fibrinogen              170-410           649                             592                           158^a^                          250^a^
  AST                     15-41             51                              112                           32                              29
  ALT                     17-63             48                              51                            10                              22
  AP                      38-126            52                              91                            36                              58
  Direct bilirubin        0.1-0.5           1.0                             0.8                           0.1                             0.2
  Indirect bilirubin      0.2-0.7           0.4                             0.9                           0.2                             0.4
  Total bilirubin         0.3-1.2           1.4                             1.7                           0.3                             0.6

aPTT = activated partial thromboplastin time, PT = prothrombin time, INR = international normalized ration, AST = aspartate amino transferase, ALT = alanine amino transferase, AP = alkaline phosphatase.

Laboratory values of COVID-19 patients on ECMO on admission (^a^denotes laboratory values obtained greater than 24 h after admission), or within 24 h prior to hemorrhage, unless otherwise noted by ^b^(obtained more than 24 h prior to the identification of hemorrhage) or ^c^(obtained after the identification of hemorrhage).

Lastly, the condition of a global pandemic has generated an unprecedented requirement for resource allocation and promotion of interventions that provide the highest value care---a function of quality, efficacy, safety, and cost. Lidegran et al^[@bib13]^ conducted a retrospective review of head CTs (CTHs) performed on patients while on ECMO.^[@bib13]^ Notably, they observed a rate of 37% of CTHs with ICH or cerebral infarction, and 13% of these with findings significant enough to motivate withdrawal of ECMO. Coupled with the 94.1% mortality of patients placed on ECMO for refractory hypoxia in the largest available cohort study of COVID-19 patients,^[@bib14]^ a compelling argument for the utilization of CTH screening in patients on ECMO for COVID-19 can be made. Portable CT has the potential to identify patients who have suffered a brain injury that would otherwise be overlooked due to the poor reliability of coagulation derangements as a clinical predictor of hemorrhage in this cohort, as well as the inability to perform neurological assessments in the setting of paralysis and sedation. This could reduce the length of time that ventilators and ECMO machines are being utilized in patients who have unknowingly suffered devastating neurological injury, increasing the availability of these scare resources for patients who retain a high probability of meaningful recovery.

CONCLUSION {#sec5}
==========

IPH is a well-described and important complication of ECMO. Despite occurring in the first 4 d on ECMO circuit,^[@bib15]^ these intracranial complications are often devastating, detected in a delayed fashion, and generally a terminal event with no indication for intervention. CT screening could be utilized to identify patients who have suffered a brain injury that would otherwise be undetected due to the poor reliability of classic coagulation markers as accurate clinical predictors of hemorrhage in this cohort, as well as the inability to perform neurological assessments in the setting of paralysis, sedation, and proning.
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